Brief: Chimeric Therapeutics Says CDH17 Granted FDA Orphan Drug Designation For Gastric Cancer
08/12/2025 24:55
Dec 8 (Reuters) - Chimeric Therapeutics Ltd CHM.AX: CDH17 GRANTED FDA ORPHAN DRUG DESIGNATION FOR GASTRIC CANCER Further company coverage: CHM.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Chimeric Therapeutics
See all newsBrief: Chimeric Therapeutics Says Phillip Hains Appointed Interim Chairman
Brief: Chimeric Therapeutics Posts Prelim Loss For Year Of A$18.8 MLN
Brief: Chimeric Therapeutics Intends To Enter Negotiations With Its Creditors
Brief: Chimeric Therapeutics Seeks Trading Halt
Australia's Chimeric Therapeutics rises on positive data for its cell therapy clinical trial